DK2915526T3 - Farmaceutiske sammensætninger, der omfatter anagrelid - Google Patents

Farmaceutiske sammensætninger, der omfatter anagrelid Download PDF

Info

Publication number
DK2915526T3
DK2915526T3 DK15158157.6T DK15158157T DK2915526T3 DK 2915526 T3 DK2915526 T3 DK 2915526T3 DK 15158157 T DK15158157 T DK 15158157T DK 2915526 T3 DK2915526 T3 DK 2915526T3
Authority
DK
Denmark
Prior art keywords
anagrelid
pharmaceutical compositions
compositions including
pharmaceutical
including anagrelid
Prior art date
Application number
DK15158157.6T
Other languages
English (en)
Inventor
Hidalgo Sergio Arroyo
Colomer Marina Puigvert
Original Assignee
Galenicum Health S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52627109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2915526(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galenicum Health S L U filed Critical Galenicum Health S L U
Application granted granted Critical
Publication of DK2915526T3 publication Critical patent/DK2915526T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15158157.6T 2014-03-07 2015-03-09 Farmaceutiske sammensætninger, der omfatter anagrelid DK2915526T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14158317 2014-03-07
EP14158312 2014-03-07

Publications (1)

Publication Number Publication Date
DK2915526T3 true DK2915526T3 (da) 2021-09-06

Family

ID=52627109

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15158157.6T DK2915526T3 (da) 2014-03-07 2015-03-09 Farmaceutiske sammensætninger, der omfatter anagrelid

Country Status (5)

Country Link
EP (1) EP2915526B1 (da)
DK (1) DK2915526T3 (da)
ES (1) ES2549106T3 (da)
HU (1) HUE055943T2 (da)
PL (1) PL2915526T3 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402613A (zh) * 2019-08-23 2021-02-26 中国科学院上海药物研究所 Pde3抑制剂与细胞因子联合治疗肿瘤的应用
WO2022060309A1 (en) * 2020-09-18 2022-03-24 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Long-term stable anagrelid capsule composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
AT10562U3 (de) 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie

Also Published As

Publication number Publication date
ES2549106T1 (es) 2015-10-23
EP2915526B1 (en) 2021-06-02
HUE055943T2 (hu) 2022-01-28
PL2915526T3 (pl) 2021-12-20
ES2549106T3 (es) 2021-12-21
EP2915526A1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
BR112016023628A2 (pt) composições farmacêuticas.
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
GB201419257D0 (en) Pharmaceutical compositions
DK3188717T3 (da) Formulering, der omfatter partikler
DK3542812T3 (da) Glycopeptidsammensætninger
BR112016026879A2 (pt) Composição farmacêutica líquida
DK3040326T3 (da) Haloolefin-baseret sammensætning
MA41107A (fr) Compositions anti-cancéreuses
DK3332767T3 (da) Flydende inhalationsformulering, der omfatter RPL554
DK3226842T3 (da) Anticancersammensætninger
DK3226843T3 (da) Anticancersammensætninger
DK3319597T3 (da) Sammensætninger, der omfatter antistof-duocarmycin-lægemiddelkonjugater
FR3024363B1 (fr) Composition thermogelifiable
DK3199161T3 (da) Farmaceutisk præparat
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
ZA201702086B (en) Long acting pharmaceutical compositions
DK3129007T3 (da) Vaccinesammensætninger
CL2017000639A1 (es) Composición
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
EA202092926A3 (ru) Лиофилизированные составы, содержащие фактор ix
DK3389633T3 (da) Farmaceutiske sammensætninger, der omfatter phenylaminopyrimidinderivat